Catheter Precision Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

VTAK$0.15-0.7%Stored close · as of Oct 2, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

Condensed Consolidated Statements of Stockholders' Equity

(in thousands, except share data)

Series A Convertible Preferred Stock · Series X Convertible Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Total Stockholders'
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Deficit	Equity
Balance at December 31, 2023	4,578	$—	12,656	$—	702,662	$—	$296,902	$(275,709)	$21,193
Stock-based compensation	—	—	—	—	—	—	6	—	6
Conversion of Series A Convertible Preferred Stock	(875)	—	—	—	54,678	—	—	—	—
Net loss	—	—	—	—	—	—	—	(2,675)	(2,675)
Balance at March 31, 2024	3,703	—	12,656	—	757,340	—	296,908	(278,384)	18,524
Stock-based compensation	—	—	—	—	—	—	13	—	13
Net loss	—	—	—	—	—	—	—	(4,220)	(4,220)
Balance at June 30, 2024	3,703	$—	12,656	$—	757,340	$—	$296,921	$(282,604)	$14,317
Issuance of common stock and other equity-classified contracts from September 2024 Public Offering, net of issuance costs	—	—	—	—	805,900	—	2,612	—	2,612
Issuance of common stock upon exercise of Pre-Funded Warrants (see Note 13)	—	—	—	—	1,658,000	—	—	—	—
Conversion of Series A Convertible Preferred Stock	(3,703)	—	—	—	231,412	—	—	—	—
Stock-based compensation	—	—	—	—	—	—	17	—	17
Net loss	—	—	—	—	—	—	—	(4,120)	(4,120)
Balance at September 30, 2024	—	$—	12,656	$—	3,452,652	$—	$299,550	$(286,724)	$12,826

Series A Convertible Preferred Stock · Series X Convertible Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Total Stockholders'
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Deficit	Equity
Balance at December 31, 2022	—	$—	—	$—	216,127	$—	$214,397	$(205,137)	$9,260
Common stock issued upon the exercise of options	—	—	—	—	30,175	—	179	—	179
Restricted stock awards cancelled	—	—	—	—	(36)	—	—	—	—
Stock-based compensation	—	—	—	—	—	—	1,394	—	1,394
Issuance of Series X Convertible Preferred Stock in merger	—	—	14,650	—	—	—	82,925	—	82,925
Conversion of Series X Convertible Preferred Stock	—	—	(1,975)	—	197,491	—	—	—	—
Issuance of Series A Convertible Preferred Stock in connection with private placement, net	7,203	—	—	—	49,791	—	7,360	—	7,360
Warrants exercised (see Note 13)	—	—	—	—	33,161	—	1,145	—	1,145
Net loss	—	—	—	—	—	—	—	(66,400)	(66,400)
Balance at March 31, 2023	7,203	—	12,675	—	526,709	—	307,400	(271,537)	35,863
Common stock issued upon the exercise of options	—	—	—	—	10,058	—	59	—	59
Adjustment of fair value of Series X Convertible Preferred Stock in merger	—	—	—	—	—	—	(10,381)	—	(10,381)
Adjustment of fair value of stock-based compensation related to merger	—	—	—	—	—	—	(174)	—	(174)
Net loss	—	—	—	—	—	—	—	(1,576)	(1,576)
Balance at June 30, 2023	7,203	—	12,675	—	536,767	—	296,904	(273,113)	23,791
Stock-based compensation	—	—	—	—	—	—	2	—	2
Conversion of Series A Convertible Preferred Stock	(2,625)	—	—	—	164,033	1	—	—	1
Net loss	—	—	—	—	—	—	—	(1,927)	(1,927)
Balance at September 30, 2023	4,578	$—	12,675	$—	700,800	$1	$296,906	$(275,040)	$21,867

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.